FDA-Approved (specific products)

Tirzepatide

Dual GIP/GLP-1 receptor agonist

This page is educational only and is not medical advice. It is not an endorsement to use this compound. See the Educational Disclaimer for details.

What It Is

A synthetic peptide that activates two gut-hormone receptor pathways (GIP and GLP-1) rather than one, distinguishing it from single-pathway GLP-1 drugs like semaglutide.

Proposed Mechanism

Dual agonism is proposed to produce greater effects on insulin secretion, appetite regulation, and energy metabolism than GLP-1 agonism alone, though the precise combined mechanism is still an active research area.

Areas Researchers Are Investigating

Comparative effectiveness vs. single-pathway GLP-1 agonists
Cardiovascular and metabolic outcomes
Effects in populations beyond the currently approved indications
Long-term durability of weight/glycemic effects

Human Evidence

Extensive — evaluated in large randomized Phase 3 trials (the SURPASS and SURMOUNT trial programs) that supported FDA approval, similar in scale to the semaglutide trial programs.

Animal / Preclinical Evidence

Standard preclinical pharmacology/toxicology package preceding human trials, consistent with the FDA drug approval pathway.

Current FDA / Regulatory Status

FDA-approved under two brand names for specific indications: Mounjaro (type 2 diabetes management) and Zepbound (chronic weight management in adults with obesity or overweight plus a weight-related condition). As with semaglutide, approval is indication- and product-specific.

Known Safety Information

Gastrointestinal side effects (nausea, vomiting, diarrhea) are the most commonly reported in trials, similar in pattern to other incretin-based therapies. Full prescribing information carries specific warnings (including thyroid tumor findings in animal studies) — general information only, not individualized guidance.

Limitations of Evidence

Manufacturer-sponsored trial programs (Eli Lilly). Head-to-head long-term comparative data against other agents is still accumulating.

Key studies and full references for this entry are still being compiled and verified — see data/peptides/tirzepatide.md in the project repo for the current compliance-review status. This page will not publish claims backed by unverified or fabricated citations.